26,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Osteosarcoma is a primary bone cancer that arises in developing bones in young adults who are experiencing growing spurts. Chemotherapy is the most common successful treatment used currently, but there are many limitations and side effects caused by these DNA damaging chemotherapies to osteosarcoma patients. The five-year survival rate for osteosarcoma is very poor in that 40% of the patients die due to their osteosarcomas and the remaining 60% who are cured of their osteosarcoma succumb to heart failure or secondary cancers. Chemotherapy regimens used to treat osteosarcoma patients result in…mehr

Produktbeschreibung
Osteosarcoma is a primary bone cancer that arises in developing bones in young adults who are experiencing growing spurts. Chemotherapy is the most common successful treatment used currently, but there are many limitations and side effects caused by these DNA damaging chemotherapies to osteosarcoma patients. The five-year survival rate for osteosarcoma is very poor in that 40% of the patients die due to their osteosarcomas and the remaining 60% who are cured of their osteosarcoma succumb to heart failure or secondary cancers. Chemotherapy regimens used to treat osteosarcoma patients result in anti-tumour activity by exerting DNA damage. This study investigated the efficacy and safety of a chosen panel of chemotherapy drugs on murine osteosarcoma (OS) cell lines.
Autorenporträt
Thanuri Jeevananda ist Mikrobiologin und Forscherin, die einen B.Sc. in Mikrobiologie und einen M.Sc. in Biotechnologie erworben hat. Ihr wissenschaftlich-technischer Hintergrund hat sie schon immer fasziniert, neue Bereiche zu erforschen, und sie hat ihre Forschung über neue Behandlungsmethoden für Osteosarkome an der La Trobe University in Melbourne erfolgreich abgeschlossen.